Longbow Finance’s LB Pharmaceuticals LBRX Stock Holding History

Longbow Finance’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-82,336	Closed	-$1.83M	–	68
2025 Q4	$1.83M	Buy	+82,336	New	+$1.44M	0.31%	60

Other funds holding LBRX

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Spruce Street Capital New York $416M AUM

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Longbow Finance's LBRX Position: Q1 2026 in Review

Longbow Finance sold out of LB Pharmaceuticals (LBRX) in Q1 2026, closing a stake of 82,336 shares — an estimated $1.83M sold.

Longbow Finance first reported a position in LBRX in Q4 2025 and held it in 1 quarter. The position peaked at $1.83M in Q4 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

Longbow Finance reported no remaining LB Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Longbow Finance sold 82,336 LB Pharmaceuticals shares in Q1 2026, an estimated $1.83M.
Longbow Finance first reported a position in LB Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Longbow Finance's LB Pharmaceuticals position peaked at $1.83M in Q4 2025.
77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Longbow Finance's 13F filing for Q1 2026, filed 12 May 2026.